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H ypertension, a complex trait determined by genetic,epigenetic, and environmental factors and their intri-
cate interaction, is an important public health challenge
worldwide because of its high prevalence and concomitant
increase in the risk for cardiovascular disease. Unfortunately,
the prevalence of hypertension is increasing in both devel-
oped and developing countries.1 As a consequence of the
increase in global prevalence, the total number of adults with
hypertension is predicted to increase to 1.56 billion in 2025.2
This prospect is daunting, given that, in 2010, high blood
pressure was already the biggest single contributor to global
mortality and disease burden.
The pathogenesis of essential hypertension is complex.
Many organs and systems including kidneys, arteries, micro-
circulation, heart, immune system, nervous system, and
endocrine factors are involved in the pathophysiology of
hypertension. Among them, kidneys and arteries are major
contributors to the development of hypertension.3,4 Various
agonists binding to plasma membrane receptors regulate renal
sodium transport and fluid balance and maintain the equilib-
rium between vasoconstriction and vasodilation. Many of
these agonists transmit their “information” via G protein–
coupled receptors (GPCRs). GPCRs mediate cellular responses
to diverse extracellular stimuli and play a vital role in the
control of physiology and behavior.5 GPCR kinases (GRKs)
interact with the agonist-activated GPCRs to promote receptor
phosphorylation and to initiate receptor desensitization.6 The
wide variety of GPCRs that are responsible for optimal blood
pressure control7 leaves no doubt that GRKs play a vital role in
the regulation of blood pressure. A number of studies have
shown that GRKs are associated with hypertension, blood
pressure response to antihypertensive medicines, and adverse
cardiovascular outcomes of antihypertensive treatment.8–11 In
this paper, we reviewed our evolving understanding of the role
of GRKs in hypertension, summarized the current knowledge
of GRK-mediated regulatory mechanisms, and highlighted the
potential for targeting GRKs in the treatment of hypertension.
This information may advance our understanding of the role of
GRKs in the control of blood pressure and provide novel
insights into the field of translational medicine, especially
regarding the design of new therapeutic approaches for the
treatment of hypertension.
Abnormal GPCR Function and Hypertension
GPCRs, the largest and most functionally diverse superfamily
of cell-surface receptors, share a common architecture
consisting of 7 transmembrane domains connected by
extracellular and intracellular loops.5 Upon stimulation,
GPCRs interact with heterotrimeric G proteins that in turn
dissociate into 2 functional units, namely, Ga and Gbc
subunits, both of which stimulate the activation of down-
stream proteins (Figure 1). In the vasculature, some GPCRs
mediate vasoconstriction and/or vascular remodeling, such
as angiotensin II (Ang II) type 1 receptor (AT1R), a-adrenergic
receptor (a-AR), endothelin A receptor, and neuropeptide Y
receptor, whereas other GPCRs induce vasodilatation and/or
inhibition of vascular remodeling, including the acetylcholine
receptor, b-AR, the endothelin B receptor, and the dopamine
receptor, among others. Similar to some renal tubular
receptors (e.g., dopamine receptor, atrial natriuretic peptide
receptor, AT2R, Mas receptor, and endothelin B receptor)
decrease renal sodium reabsorption, whereas others including
the AT1R, insulin receptor, and mineralocorticoid receptor
increase renal sodium reabsorption. The balance between pro-
and antihypertensive receptor activity is important to keep the
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blood pressure in the normal range. Abnormal GPCR functions
lead to increased blood pressure; for example, increased AT1R
function and impaired dopamine receptor function are found
in hypertensive patients and hypertensive animal models.12,13
The causes of abnormal GPCR function are complex and may
include perturbation of DNA modification, receptor expres-
sion, and phosphorylation.14,15 Among these modifications,
GPCR phosphorylation is important. In hypertensive states, for
example, dopamine D1 receptor (D1R) is hyperphosphorylated,
which leads to uncoupling of the dopamine receptor from its
GaS/effector protein complex and impairment of dopamine-
mediated natriuresis and vasodilation.13,15,16 It is known that
the state of phosphorylation of GPCRs is modified by 2 kinds
of enzymes. Kinases (e.g., GRKs) increase GPCR phosphory-
lation, whereas phosphatases (e.g., protein phosphatase 2A)
bring about GPCR dephosphorylation. Renal protein phos-
phatase 2A activity is decreased in adult spontaneously
hypertensive rats (SHRs) but increased in young (aged
2 weeks) SHRs, whereas GRK4 activity is markedly increased
in hypertension.16-18 Nevertheless, the GRKs have received,
by far, the most attention in abnormal GPCR phosphorylation
in renal tubules in hypertension.
Role of GRKs in the Regulation of Blood
Pressure
GRK Family Members
Although there are>800 knownGPCRs in the human genome, it
is surprising that only 7 GRKs (GRK1–7) have been identified.
The GRKs constitute a family of 7 serine/threonine protein
kinases characterized by their ability to specifically recognize
and phosphorylate agonist-activated GPCRs. Based on diver-
gent C-terminal domain architecture and membrane-targeting
mechanisms, the GRKs are classified into 3 subfamilies: (1) the
GRK1 subfamily, also known as the opsin kinase family,
consisting of the rhodopsin kinase GRK1 and visual pigment
kinase GRK7; (2) the GRK2-like subfamily, also known as the b-
AR kinase family, consisting of GRK2 (b-AR kinase 1) and GRK3
(b-AR kinase 2); and (3) the GRK4-like subfamily, consisting of
GRK4, GRK5, and GRK6.6 All GRKs possess similar structural
organization with an N-terminal domain (185 amino acids), a
catalytic domain (270 amino acids), and a C-terminal domain
(105–230 amino acids) (Figure 2). The carboxy tail region is
GRK subtype-specific; it is prenylated in the GRK1 subfamily,
binds to Gbc, contains a pleckstrin homology domain in the
Figure 1. Schematic representation of the process of GPCR desensitization. On binding
to their cognate ligands, GPCR activation initiates dissociation of cognate trimeric G
protein, promoting GPCR phosphorylation by GRKs, leading to receptor association with
members of the arrestin family, which inhibits further G protein activation. AC indicates
adenylyl cyclase; GDP, Guanosine-50-diphosphate; GIRK, G protein–gated inwardly rectifying
potassium channel; GPCR, G protein–coupled receptor; GRK, G protein–coupled receptor
kinase; GTP, Guanosine-50-triphosphate; MEKs, mitogen-activated protein/extracellular
signal-regulated protein kinase kinases; P, phosphorylation; PI3K, phosphatidylinositol-3
kinase; PKA, protein kinase A.
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GRK2 subfamily, and has a C-terminal helix/palmitoylation site
in the GRK4 subfamily.6 The C-terminal domain of GRKs is the
most important determinant of subcellular localization and
agonist-dependent translocation.19 There is a nuclear localiza-
tion sequence in all members of the GRK4 subfamily; the
nuclear localization sequence in GRK5 and GRK6, but not GRK4,
binds to DNA in vitro.20
The distribution of GRK subtype expression is different
among subtypes. GRK1, GRK4, and GRK7 are expressed in
limited numbers of tissues. GRK1 and GRK7 are found almost
exclusively in the retina and regulate the opsins. GRK4 is
expressed in testis, myometrium, kidney, artery, and intes-
tine.13,15–18,21 By contrast, other GRKs (GRK2, GRK3, GRK5,
and GRK6) are expressed ubiquitously throughout the body.
Accordingly, except for GRK1 and GRK7, other GRK members
(GRK2–6) exert different physiological effects, specifically, the
regulation of blood pressure by the cardiovascular system and
the kidney.8–11,16–18,20–24
G protein–coupled receptor kinase 2
The human GRK2 (official name ADRBK1) gene locus maps at
the long arm of chromosome 11: 11q13.2 by Ensembl, 11q13.1
by Entrez Gene (National Center for Biotechnology Information),
and 11q13 by the HUGO Gene Nomenclature Committee
(HGNC). Human GRK2 cDNA encodes a protein of 689 amino
acids (79.573 kDa) with an overall 98.0% amino acid and 92.5%
nucleotide identity with bovine GRK2. The 23-kb human GRK2
gene consists of 21 exons interrupted by 20 introns, with a
predicted transcription start site 246 bases upstream of the
start ATG. The human GRK2 gene has 12 highly conserved
catalytic region subdomains in which 5 are encoded entirely
within exons, specifically, exons 8, 9, 10, 11, and 12. Exons
bounded by introns range in size from 52 (exon 7) to 163 bases
(exon 18). The 2 largest exons represent the 50-flanking region
(359bases, including 113 bases of coding sequence) and the 30-
coding plus noncoding region of the gene (>1200 bases).
Sequence analysis of the 50-flanking/promoter region reveals
many features characteristic of mammalian housekeeping
genes, namely, the lack of a TATA box, an absent or
nonstandardly positioned CAAT box, high GC content, and the
presence of Sp1-binding sites. The conserved region of the C-
terminal domain is important for enzyme–receptor interaction
required for GRK2 to catalyze receptor phosphorylation.25 In
addition, a Gbc binding site of GRK2 is also localized in the C-
terminal pleckstrin homology domain. Phosphorylated Raf
kinase inhibitory protein binds to the N terminus of GRK2,
resulting in the inhibition of its function.26
Distribution of GRK2. GRK2 is ubiquitously expressed in
mammals. In the cardiovascular system, GRK2 is expressed in
the vascular endothelium, arterial smooth muscle, and
myocardium.27,28 GRK2 is also abundant in the kidney,
especially in the renal proximal tubule.29 This renal expression
indicates that GRK2 plays a vital role in the regulation of ion
and fluid transport and, ultimately, blood pressure. GRK2 is
expressed in both cytoplasm and the cell membrane. It
shuttles between the cytosol and plasma membrane, anchor-
ing to the latter through its pleckstrin homology and Gbc
binding domains at the C-terminus.30 The subcellular local-
ization of GRK2 at the mitochondrial outer membrane27,31
may indicate a role of GRK2 in regulating mitochondrial
biogenesis and cellular energy production. Indeed, GRK2
increases mitochondrial superoxide production and decreases
oxygen consumption and ATP production.32
Regulation of GRK2 in the regulation of blood pressure.
A role of GRK2 in the regulation of blood pressure has been
shown in animalmodels with partial germline deletion, universal
GRK2 knockdown, and targeted overexpression or knockdown
in vascular smooth muscle and endothelial cells.22,33–36 GRK2
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Figure 2. Structural domain distribution of GRKs. All GRKs
possess an N-terminal domain and a catalytic domain, both of
which are followed by a Regulator of G protein signaling (RGS)
homology domain, and a C-terminal domain. GRK2 and GRK3 have
another PH domain that interacts with G protein bc subunits. The
various isoforms of human GRK4 (GRK4a, GRK4b, GRK4c, and
GRK4d) have differences in presence or in-frame deletion of certain
exons. The solid black square represents the presence of exon 2
and/or exon 15, whereas the dotted square represents the deletion
of exon 2 and/or exon 15. GRK indicates G protein–coupled
receptor kinase; PH, pleckstrin homology; RH, RGS homology.
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plays an important role in the regulation of blood pressure.7
Germline deletion of Grk2 is lethal.37 GRK2 deficiency in global
adult hemizygous mice (Grk2+/) has no effect on basal blood
pressure but increases the vasodilator response to acetyl-
choline or isoproterenol and protects against Ang II–induced
hypertension and vascular remodeling that is partially caused
by increased nitric oxide bioavailability.33 Cohn et al also found
in mice that inhibition of vascular smooth muscle GRK2 by
either overexpression of the C-terminal portion of GRK2 or
vascular smooth muscle–specific ablation of GRK2 protein
expression has no effect on blood pressure.35 This method of
GRK2 silencing also had no effect on the elevated blood
pressure resulting from unilateral renal artery stenosis.35 In
contrast, overexpression of GRK2 in vascular smooth muscle in
mice increases resting blood pressure.34 This study would
agree with the report that GRK2 inhibits adiponectin function;
adiponectin may be antihypertensive.38,39 Portal hypertension
caused by common bile duct ligation is also associated with an
increase in GRK2 expression in the mesenteric artery.40
Consequently, deletion of GRK2 should result in a decrease in
blood pressure; However, global knockdown ofGrk2 expression
using small hairpin interfering RNA in male mice produces
hypertension that is associated with vascular remodeling
caused in part by increases in cell proliferation at age 6 months
but not at 3 months.22 The causes of the differences are not
known, but the differential effects of GRK2 on vasoconstriction
and vasodilation may explain this apparently conflicting results.
In small hairpin Grk2 knockdown mice, for example, both
phenylephrine-induced contractile responses and isopro-
terenol-mediated vasodilation are increased; which one dom-
inates would eventually determine the physiological
phenotype.22 After inhibition of GRK2 by either peptide
inhibition or gene ablation, downregulation of GRK2 does not
only increase b-AR–mediated vasodilation but also enhances
a1D-AR–stimulated vasoconstriction and could explain the lack
of effect on blood pressure of a decrease in GRK2 expression or
function.35 Whether or not the discrepant results could be
related to sex differences were not determined, but the small
hairpin Grk2 studies were performed only in male mice because
theGrk2 small hairpin RNA transgene was incorporated into the
Y chromosome22; the sexes of the mice in the other studies
were not given. Nevertheless, the transgenic overexpression of
GRK5 in vascular smooth muscle increases blood pressure to a
greater extent in male than in female mice.23 The discrepant
results may also be related to the extent of downregulation of
GRK2 in different tissues.
GRK2 is expressed to a greater extent than GRK5 in
endothelial cells.41 Increased GRK2 expression in injured
endothelial cells in injured liver leads to intrahepatic portal
hypertension, and knockdown of GRK2 in liver sinusoidal
endothelial cells leads to an increase in portal pressure that is
related to decreased endothelial nitric oxide synthase
production of nitric oxide.36 Selective deletion of Grk2 in
the endothelium affects the aorta’s receptor-dependent and -
independent vasoconstriction and increases vascular inflam-
mation and tissue degeneration by increasing mitochondrial
reactive oxygen species production, which is also associated
with hypertension.42 Exercise decreases blood pressure,
improves insulin sensitivity, and decreases mesenteric arte-
riolar and myocardial GRK2 expression in SHRs.43 The effects
in mesenteric arterioles were prevented by mesenteric
arteriolar overexpression of GRK2. In contrast, downregula-
tion of endothelial vascular GRK2 expression in SHRs that is
initiated at the prehypertensive stage (age 4 weeks) subse-
quently improves vascular insulin sensitivity that helps to limit
the progression of hypertension.43 GRK2 impairs insulin
sensitivity by binding to the insulin receptor substrate 1 but
not to the insulin receptor.44 GRK2 expression in renal
preglomerular vessels increases with aging in male but not in
female rats.45 GRK2 regulates the blood pressure by modu-
lating other receptor-mediated vascular responses, including
endothelin A receptor, neurotensin receptor 1, and P2Y
receptor.46–48 The reasons why knockdown of GRK2 in mice
in different studies leads to different effects on blood
pressure need to be elucidated.
GRK2 also plays an important role in the renal regulation of
sodium excretion and blood pressure. GRK2 keeps amiloride-
sensitive epithelial Na+ channels in the active state.49–51 GRK2
upregulates epithelial Na+ channel activity by a mechanism
that depends not on its kinase activity but rather on the ability
of the RGS homology domain of GRK2 to interact with and
inhibit the a subunit of Gq/11, a negative regulator of
epithelial Na+ channels.50 GRK2-mediated phosphorylation of
the C-terminus of b–epithelial Na+ channels and phosphory-
lation of Nedd4-2 prevent its ability to inhibit epithelial Na+
channel activity.51,52 GRK2 negatively regulates neurotensin
receptor 1 function; there are more neurotensin binding sites
in the renal cortex than in the renal medulla, and they decrease
sodium excretion, but the mechanism is not known.47 GRK2
also regulates the phosphorylation of renal D1R and D1R-
mediated natriuresis.53 In the human kidney, antisense
oligonucleotides against GRK2 and GRK4 blunt the later
stages of D1R desensitization; heparin, a nonselective GRK
inhibitor, decreases GRK2 and GRK4 expression and attenu-
ates the desensitization of D1R.
54 Both GRK2 and GRK4 are
involved in the desensitization of renal D1R in obese Zucker
rats.55 Oxidative stress is involved in the regulation of GRK2 of
D1R.
56 Both in vivo and in vitro studies show that oxidative
stress activates nuclear factor jB, causing an increase in
protein kinase c (PKC) activity, which leads to GRK2 translo-
cation and subsequent D1R serine hyperphosphorylation.
56
The functional consequence of this phenomenon is the
inability of D1R to inhibit Na
+,K+-ATPase activity and promote
sodium excretion, which could contribute to the increase in
DOI: 10.1161/JAHA.116.003519 Journal of the American Heart Association 4




























blood pressure.56 Interestingly, we recently found that prena-
tal lipopolysaccharide exposure results in increased GRK2
expression, increased D1R phosphorylation, and impaired D1R-
mediated natriuresis and diuresis in the offspring. These
findings suggest that a dysfunction of the renal D1R induced by
abnormal GRK2 expression is also involved in fetal-pro-
grammed hypertension.57 GRK2 is also involved in desensiti-
zation of D2R; D2R dysfunction is involved in the pathogenesis
of hypertension.58,59
Role of GRK2 in spontaneous hypertension. GRK2
expression in several tissues is increased in several diseases,
including spontaneous hypertension in humans and experimen-
tal animals and in animal models of diabetes and insulin
resistance.28 Gros et al reported that in SHRs, GRK2 expression
is increased in both lymphocytes and aortic vascular smooth
muscle cells and is accompanied by impairment of
b-adrenergic–mediated stimulation of adenylyl cyclase activity
and b-AR–mediated vasodilation.60 The impairment in
b-adrenergic–mediated aortic vasodilation and increased vas-
cular GRK2 expression are observed in SHRs aged 10 and
15 weeks but not 5 weeks. Increased aortic vascular GRK2
expression is also present in the Dahl salt-sensitive hyperten-
sive rats after 4 weeks of a high salt diet.60 Oliver et al also
reported impaired aortic b1- and b2-AR–mediated vasodilation,
but not b3-AR–mediated vasodilatation, and increased aortic
expression of GRK2 in adult SHRs61; however, this group did not
find such differences in the mesenteric artery of adult Wistar-
Kyoto (WKY) rats and SHRs.61 Moreover, in rats made hyper-
tensive by L-NAME, their aortas had increased b2-AR–mediated
vasodilation and decreased GRK2 expression; their mesenteric
arteries had decreased b2-AR-mediated vasodilation, without
changes inGRK2expression—opposite to that found in SHRs.61
Whether or not inconsistencies are present in other models of
hypertension remain to be determined.
GRK2 is expressed in peripheral blood mononuclear cells
and lymphocytes.7,62 GRK activity and GRK2 expression are
increased in lymphocytes of hypertensive humans and
experimental models of hypertension.60,63,64 Lymphocyte
GRK2 mRNA expression directly correlates with systolic blood
pressure and plasma norepinephrine levels.64 GRK2 in
lymphocytes is elevated >30% among persons with systolic
blood pressure >130 mm Hg. GRK2 protein expression in
lymphocytes is also increased about 2-fold, and its activity
increased >40% in African Americans, a population at higher
risk for hypertension and cardiovascular complications com-
pared with other groups.64
G protein–coupled receptor kinase 3
The human GRK3 (official name ADRBK2) gene locus maps at
the long arm of chromosome 22: 22q12.1 by Ensembl and
Entrez Gene and 22q11 by HGNC. Similar to GRK2, the GRK3
gene also has 21 exons ranging in size from 52 to 163 bases.
The amino acid sequence of human GRK3 is 84%, identical to
that of human GRK2. Similarly, bovine GRK3 has 85% amino
acid identity with GRK2. The most highly conserved region
between GRK3 and GRK2 is the protein kinase catalytic
domain, which has only 12 amino acid differences (95.0%
identity), 4 of which are conservative substitutions (96.7%
conservative). In contrast, the amino-terminal domain (80.7%
identity, 89.8% conservative) and carboxyl-terminal domain
(76.6% identity, 88.9% conservative) are less well conserved.
GRK3 belongs to the GRK2 subfamily and is ubiquitously
expressed in the body; however, unlike GRK2 and GRK5,
GRK3 is not expressed in endothelial cells.41 In contrast, in
cardiac myocytes, the GRK2 subfamily expression is GRK5 to
GRK3 to GRK2. Many studies have focused on the role of
GRK2 and GRK3 on cardiac function.8,65 GRK3 and GRK2,
however, have distinct roles in receptor selectivity in cardiac
myocytes and receptor-mediated regulation of cardiac func-
tion; GRK3 has selectivity for the a1B-ARs and for the
thrombin receptor but exhibits less efficacy at b1-ARs than
GRK2.65 Their subcellular distribution in cardiac myocytes is
also different. Consequently, GRK2 expression is increased in
intercalated discs in rats with spontaneously hypertensive
heart failure, whereas GRK3 expression is increased in cross-
striations in a-actinin and Ga at Z-lines.66
Unlike the prohypertensive action of GRK2,33,34 GRK3 may
play a protective role in the regulation of blood pressure.
Cardiac myocytes of spontaneously hypertensive heart failure
rats have increased expression of GRK3 and GRK6 and altered
distribution, including that of GRK2.66 GRK3 expression in
human lymphocytes significantly and inversely correlates with
systolic and diastolic ambulatory blood pressure.9 The
protective role for GRK3 in the regulation of blood pressure
is supported by findings in transgenic mice in which cardiac
myocyte–restricted inhibition of endogenous GRK3 causes
hypertension because of increased cardiac output caused in
part by cardiac myocyte a1-AR hyperresponsiveness.
67 GRK3
is important in a1B-AR signaling; GRK5 has a partial effect,
whereas GRK2 has no effect.68 Although a-ARs are key
regulators of vascular resistance and GRK3 is expressed in
the vasculature, it remains unknown whether or not GRK3 can
regulate the blood pressure by exerting some functions in
vascular resistance. In addition, GRK3 reportedly regulates
the phosphorylation of D1R
53 and D2R; however, its physio-
logical consequence is not clear.
G protein–coupled receptor kinase 4
The human GRK4 gene locus (4p16.3) is embedded in a gene
cluster region on chromosome 4p16 that includes genes
encoding dopamine receptor type 5 (4.p16.1) and a-adducin
DOI: 10.1161/JAHA.116.003519 Journal of the American Heart Association 5




























(4p16.3), 2 variants of which (ADD1 and GRK4) are linked to
hypertension.16,69,70 The human GRK4 gene is composed of
16 exons extending over 75 kb of DNA. Alternative splicing
generates 4 isoforms of human GRK4 mRNA that differ in the
presence or absence of exon 2 at the N-terminal region and
exon 15 in the C-terminal region: GRK4a (578 amino acids,
66.5 kDa) is the full-length isoform; GRK4b (546 amino acids,
62.9 kDa) lacks only the N-terminal exon 2 (32-codon
deletion); GRK4c (532 amino acids, 61.2 kDa) lacks only
the C-terminal exon 15 (46-codon deletion); and the shortest
splice variant is GRK4d (500 amino acids, 57.6 kDa), missing
both exons 2 and 15.71 In addition, 5 GRK4 splice variants
(GRK4A–E) in rat and only 1 GRK4 splice in mouse have been
reported. Only the GRKa isoform in humans, GRK4A in rats,
and only GRK4 reported in mice are closely homologous
(70%), whereas the mouse and rat GRK4 sequences retain
90% identity.
Distribution of GRK4. As noted previously, GRK2, GRK3,
GRK5, and GRK6 are ubiquitously expressed, whereas GRK4 is
expressed in a limited number of tissues. GRK4, for example,
is abundantly expressed in the testes and human myometrium
and, to a lesser extent, in a few other tissues, including the
artery, brain, kidney, and intestine, but has minimal expression
in the normal heart.16,71,72 The distinct distribution of GRK4
indicates its vital role in the regulation of blood pressure. In
both WKY rats and SHRs, GRK4 expression is strongly
expressed in subapical membranes of renal proximal tubules
(S1 and S3 segments), thick ascending limbs of the loop of
Henle, and the distal convoluted tubules and much less in
glomeruli.16,72,73 GRK4 is also present in rat renal resistance
vessels, but its physiological function remains unclear. Basal
GRK4 expression in the renal cortex is much higher in SHRs
than in WKY rats, whereas cardiac GRK4 expression is similar
in the 2 rat strains, indicating that the increased GRK4
expression in hypertension has organ specificity.72
In our recent studies, we found that GRK4 is also
expressed in the tunica media and adventitia of arteries from
Sprague-Dawley rats and C57BL/6J mice.21 GRK4 is
expressed in both large and small vessels, including the
thoracic aorta, superior mesenteric artery, carotid arteries,
and renal artery, and there is no difference in GRK4
expression in these vessels. The physiological significance
of GRK4 at the tunica adventitia, however, remains to be
determined because GRK4 in this layer does not participate in
the Ang II–mediated vasoconstriction.21 In addition, we found
that GRK4 is expressed in the myocardium, which is involved
in the regulation of myocardial ischemia. Overexpression of
GRK4 or its variants in mice contributes to the aggravation of
the ischemia induced by myocardial injury (L.P. Li, J. Yang, and
C.Y. Zeng Ph.D., unpublished data, 2016).
Regulation by GRK4 of blood pressure. The dopaminergic
system and the renin–angiotensin system are important
regulators of sodium balance and blood pressure, which are
relevant to the pathogenesis and/or maintenance of hyper-
tension.13,15–18,54–57,59,71–78 The dopaminergic system exerts
a paracrine regulatory role on renal sodium transport in the
proximal tubule via its 5 receptor subtypes. Dopamine
receptors, pharmacologically grouped into D1-like (D1 and
D5) and D2-like (D2, D3, and D4) receptors, as with the Ang II
receptors (AT1R and AT2R), are expressed in brush border and
basolateral membranes of renal proximal tubules. AT1R
mediates the vast majority of renal actions of Ang II, including
renal tubule sodium reabsorption. In contrast to the
stimulatory effect of Ang II on sodium transport in renal
proximal tubules, the major consequence of the activation of
dopamine receptors is the inhibition of sodium trans-
port.13,15–18,54–57,59,71–78 Increasingly, studies show that
GRK4 plays an important physiological role in the long-term
control of blood pressure and in sodium homoeostasis via the
regulation of the renal D1R, D3R, and AT1R.
Studies have shown that increased GRK4 activity causes
impaired renal D1R function in hypertension. GRK4 activity is
increased in the kidneys of humans with essential hyperten-
sion, but the increased activity is caused not by increased
renal GRK4 protein expression but rather by constitutively
active variants of GRK4.16 In human renal proximal tubule
cells, GRK4 constitutively phosphorylates the D1R in the
absence of agonist activation; however, inhibition of GRK4
activity or depletion of GRK4 blunts the D1R desensitization.
54
The abundance of basal GRK4 and serine-phosphorylated D1R
in renal cortical membranes are much higher in SHRs relative
to WKY rats.72 Selective renal cortical inhibition of GRK4
expression decreases serine-phosphorylated D1R to a greater
extent in SHRs than in WKY rats; it also increases sodium
excretion and attenuates the increase in arterial blood
pressure with age in SHRs but not in WKY rats.72 Similar to
GRK2, the dysfunction of the renal D1R induced by abnormal
GRK4 expression is also involved in fetal-programmed hyper-
tension.57 In renal proximal tubules, however, GRK4 is more
important than other GRKs in the desensitization of D1R and
D3R.
54,73 These findings suggest the crucial role of renal
GRK4 in the D1R- and D3R-mediated control of sodium
excretion and blood pressure.
The 3 human GRK4c single nucleotide polymorphisms
(SNPs; 65R>L, 142A>V, and 486A>V) markedly impair D1R-
mediated cAMP accumulation in the kidney, which is not due
to differences in the quantity of the expression of either D1R
or GRK4.16 Compared with GRK4c wild-type transgenic mice,
GRK4c142V transgenic mice are hypertensive and fail to
increase urine flow and sodium excretion in response to the
D1R agonist fenoldopam; the decreased ability of fenoldopam
DOI: 10.1161/JAHA.116.003519 Journal of the American Heart Association 6




























to inhibit renal sodium transport is also observed in vitro.16
The increase in blood pressure in GRK4c142V transgenic
mice is not related to chromosomal integration, copy number,
or renal human GRK4 mRNA level but rather is mainly caused
by the effect of the GRK4c142V transgene acting via D1R.
76 In
vitro studies showed that in single-variant (142A>V, 65R>L, or
486A>V) or double-variant (65L/486V) GRK4c-transfected
Chinese hamster ovary cells, there is an increase in basal D1R
phosphorylation and impairment of D1R-mediated cAMP
production.16 We also found that the function of D3R is also
impaired in the GRK4c142V-transfected human renal proximal
tubule cells (J. Yang, MD, PhD, et al, unpublished data, 2016).
In addition to GRK4 regulation of D1R and D3R in the renal
proximal tubule, there is also evidence that GRK4 regulates
AT1R expression and activity in this nephron segment. The
GRK4 gene variants that are associated with hypertension
increase renal proximal tubule AT1R expression and activity. In
GRK4c142V transgenic mice, due to the inhibition of renal
histone deacetylase type 1 (but not histone deacetylase type
2) activity, renal AT1R expression and activity are increased,
which leads to increased blood pressure. In contrast, AT1R
blockade or deletion of the AT1R gene normalizes the
hypertension in GRK4c142V transgenic mice.77 Our recent
study also showed that, due to higher nuclear factor jB activity
with more nuclear factor jB bound to the AT1R promoter, both
AT1R expression and AT1R-mediated vasoconstriction are
higher in the aorta of GRK4c142V than GRK4c wild-type
transgenic mice.21 In GRK4c142V transgenic mice. Ang II
causes a greater increase in systolic blood pressure, whereas
infusion of the AT1R antagonist candesartan causes a greater
decrease in blood pressure in GRK4c142V transgenic mice
than their wild-type counterparts.21,77 Similarly, renal AT1R
expression is also enhanced in GRK4c486V transgenic mice
fed a high salt diet, which may contribute to the salt-sensitive
phenotype of these mice; however, the GRK4c wild-type
transgene prevents salt-sensitive hypertension.77,78
Role of GRK4 in human essential hypertension. The
GRK4 locus on human chromosome 4p16.3 is linked to
essential hypertension and salt sensitivity.79–85 Three mis-
sense SNPs ( ie, 65R>L, 142A>V, and 486A>V) in the coding
region of GRK4c are associated with increased blood
pressure. Depending on the genetic background of the
mouse, mice overexpressing the GRK4c wild-type transgene
are normotensive and salt-resistant, whereas GRK4c142V
transgenic mice have high blood pressure even with normal
NaCl intake.16,76,77 In contrast, GRK4c486V or GRK4c65L
transgenic mice become hypertensive only after an increase
in sodium intake.77,78
A number of studies have shown the genetic association of
the 3 GRK4 SNPs with human essential hypertension in
several ethnic groups. The association between GRK4486V
and essential hypertension was found in Italian and Euro-
Australian populations.79,80 In a study of northern Han
Chinese participants, the GRK465L, GRK4142V, and
GRK4A486 haplotypes are associated with a 6-fold higher
risk of systolic and diastolic hypertension.81 In these same
Han Chinese participants, GRK4486V alone is associated with
hypertension.82 In an African-derived semi-isolated Brazilian
population, the combination of NOS3 rs1799983 and
GRK4486V is associated with hypertension.83 GRK4486V is
also associated with salt sensitivity in a Euro-American
population.84 In a Japanese cohort, the presence of all 3
GRK4 variants impaired the natriuretic effect of a dopamin-
ergic agonist and correctly predicted the presence of
salt-sensitive hypertension in 94% of cases.85 The single-
locus model with only GRK4142V is 78.4% predictive, whereas
a 2-locus model of GRK4142V and aldosterone synthase
CYP11B2 is 77.8% predictive of low-renin hypertension.85
Some reports, however, do not show the association between
GRK4 variants and hypertension that may be related to the
failure to study all of the GRK4 variants or to the age of the
participants.86,87
G protein–coupled receptor kinase 5
The human GRK5 gene locus maps to the long arm of
chromosome 10: 10q26.11 by Ensembl, Entrez Gene, and
HGNC. GRK5, a 590-amino acid protein kinase, has 34.8% and
47.2% amino acid identities with GRK2 and GRK1, respec-
tively. GRK5 contains a centrally located protein kinase
catalytic domain of 238 amino acid residues flanked by N-
terminal and C-terminal regions of 193 and 159 amino acid
residues, respectively. The atomic structure of GRK5 has been
shown to be aligned in manner different from the other
GRKs.88 GRK5 mRNA is found most abundantly in the lung,
heart, retina, and lingual epithelium but is minimally
expressed in brain, liver, kidney, and testis. Many studies of
GRK5 have focused on its role in the exacerbation of
pathological cardiac hypertrophy89; however, GRK5 is also
involved in the pathogenesis of hypertension. GRK5, as with
GRK2, for example, is also increased in lymphocytes from
hypertensive humans and animal models of hypertension.90
The intracardiac injection of adenovirus encoding the
amino-terminal region of GRK5 increases the already elevated
blood pressure of SHRs.91 GRK5 overexpression in vascular
smooth muscle cells in mice increases blood pressure. The
hypertension in male GRK5 transgenic mice is caused in part
by a decrease in b1-AR activity, whereas high blood pressure
in female mice is caused by an increase in activity of AT1R.
23
Grk5 knockout mice have impaired glucose tolerance and
insulin sensitivity, indicating that GRK5 is a positive regulator
of insulin sensitivity.92 Increased expression of GRK5 is
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associated with different animal models of hypertension,
including Ang II-, norepinephrine-, and L-NAME–induced
hypertension.93,94 There is a nuclear redistribution of GRK5
in hypertensive heart-failure-prone rats.95 The physical asso-
ciation of AT1R and GRK5 is increased in the heart in
congestive heart failure but is reversed by exercise training.96
In vitro studies showed that both AT1R and D1R can be the
substrates for GRK5. The agonist-dependent phosphorylation
of the AT1R is substantially increased in human embryonic
kidney cells overexpressing GRK5, GRK2, or GRK3.97 GRK4
and GRK5 impair both the sensitivity and maximum response
of D1R, whereas GRK2 and GRK3 impair only the sensitivity of
D1R to agonist stimulation.
16,98 Whereas HDAC1 is involved in
the increase in GRK4c142A>V-mediated increase in renal
AT1R expression,
77 HDAC5 is associated with the GRK5-
regulated gene transcription in heart failure.99
GRK5Leu41 is a nonsynonymous polymorphism of GRK5,
common in African-Americans, in which leucine is substituted
for glutamine at position 41. A study showed that the
GRK5Leu41 polymorphism decreased the risk for adverse
cardiovascular response but not for the blood pressure
response to antihypertensive medication.100 Another study
showed a pharmacogenomic interaction between GRK5Leu41
and b-AR-blocker treatment in which the presence of the
GRK5Leu41 polymorphism was associated with decreased
mortality in African-Americans with heart failure or cardiac
ischemia.101
G protein–coupled receptor kinase 6
The human GRK6 gene locus maps to the long arm of
chromosome 5: 5q35.3 by Ensembl, 5q35 by Entrez Gene,
and 5q35 by HGNC. The crystal structure of GRK6 has been
deciphered.102 GRK6 has higher homology with GRK5 (70.1%
amino acid identity) compared with GRK2 (37.4%) and GRK1
(47.1%).The structure of GRK6 reveals a putative phospholipid
binding site near the N-terminus and structural elements
within the kinase substrate channel that influence GPCR
access and specificity.102 GRK6 is expressed ubiquitously
throughout the body, including the brain, skeletal muscle,
pancreas, and myometrium and at lower levels in the heart,
lung, kidney, placenta, and liver.
As with the other GRKs, GRK6 also regulates the b-AR and
AT1R.
103–105 GRK6 but not GRK2 or GRK5 is involved in the
desensitization of calcitonin gene-related peptide.106
GRK6 also regulates Na+/H+ exchanger regulatory factor107;
Na+/H+ exchanger regulatory factor and Na+/H+ exchanger
type 3 are involved in the regulation of renal sodium transport.
Although D1-like receptor-mediated inhibition of renal sodium
Na+/K+/ATPase activity requires Na+/H+ exchanger regula-
tory factor 1,108 and dopamine receptors are important in the
regulation of renal sodium transport and blood pressure,59,74
Na+/H+ exchanger regulatory factor 1 per se does not
regulate blood pressure.109 Both D1- and D2-like dopamine
receptors are physiological targets of GRK6. Inhibition of
GRK6 prevents agonist-induced desensitization of intestinal
D1-like receptors in rat intestinal epithelial cells.
107 Dopamine
D2R hypersensitivity occurs with disruption of the GRK6 gene
in mice.110 Consequently, abnormalities of the GRK6 gene can
lead to D2R supersensitivity, which can result in dysfunction
of D2R in the regulation of natriuresis and blood pressure.
The expression of GRK6 is affected by hypertensive status
and associated with hypertension-induced complications.
Renal GRK6 levels are lower in hypertensive participants
and SHRs than their normotensive controls111; however,
GRK6 expression is increased in spontaneously hypertensive
heart failure rats.66 Moreover, subcellular redistribution of
GRK6 in spontaneously hypertensive heart failure rats is also
involved in abnormal remodeling of cardiac myocytes in
hypertensive hypertrophy and failure.66 GRK6 is also impor-
tant in the negative regulation of inflammation,112 which is
intimately involved in the regulation of blood pressure and
development of hypertension.
GRK Gene Variants and Their Roles in
Hypertension
Since the discovery of a linkage between GRKs and cardio-
vascular disease including hypertension and heart failure,
GRKs—especially GRK2 and GRK4—have been considered
pharmaceutical targets for the treatment of cardiovascular
disease. Moreover, GRK gene variants are also important for
guiding therapeutic antihypertensive strategies.100,113
Current evidence shows that common variants of GRK4 are
associated with human essential hypertension and predict the
blood pressure response to antihypertensive medicines. Our
recent study in hypertensive Japanese participants showed
that carriers of GRK4142V had a greater decrease in systolic
blood pressure in response to angiotensin receptor blockers
than noncarrier hypertensive patients. In contrast, those with
variants only at GRK4486V were less likely to achieve the
blood pressure goal in response to angiotensin receptor
blockers than those with no variants.10 Nevertheless, in a
small cohort of Japanese hypertensive participants, those with
GRK4486V has a good antihypertensive response to a low-salt
diet or diuretics.114 The association between GRK4 variants
and the response to antihypertensive treatment has also been
confirmed in American and European hypertensive partici-
pants. Results from the African American Study of Kidney
Disease and Hypertension Study suggest a sex-specific
relationship between GRK4A142V and blood pressure
response among African-American men with early hyperten-
sive nephrosclerosis. Men with GRK4A142 were less
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Table. Summary of GRK Family and Hypertension
GRK Isoform Tissue Distribution GRK Modification
Effects of GRK Modification on Blood
Pressure and Related GPCRs






Impairs b-AR induced vasodilation34;
increases resting blood pressure34
Increased GRK2 expression and GRK activity
in lymphocytes and arteries in
hypertensive patients and SHRs60,63,64;
increased GRK2 expression in
conductance and resistance vessels in
SHRs61,117; decreased GRK2 expression in
conductance vessels and no change in
GRK2 expression in resistance vessels in
L-NAME- induced hypertensive rats61;
increased GRK2 expression and GRK
activity in mesenteric artery of sedentary
SHRs43; increased renal GRK2 expression
in obese rats29; increased renal GRK2




No effect on baseline blood pressure but
protects against Ang II–induced
hypertension and vascular remodeling33
Global knockdown
using a shRNA
Results in spontaneous hypertension22;
increases both vasoconstriction in
response to PE and vasodilatation in
response to b-AR stimulation22
VSMC-specific
ablation of GRK2
No effect on baseline blood pressure35;
increases b-AR–mediated vasodilation,




Blood pressure not measured; blunts





Blunts desensitization of arterial ETAR46;
promotes insulin-induced vasodilation of
mesenteric arteries in SHRs43; blunts







Increases blood pressure and cardiac
output67; increased cardiac myocyte a1-AR
responsiveness67; attenuates cardiac
dysfunction caused by pressure overload24
No significant difference in GRK3
expression in the lymphocytes of






Increases blood pressure (normal salt
diet)16,77; impairs renal D1R function
16;
increases AT1R expression in the kidney
and artery21,77; increases in systolic blood
pressure response to Ang II21
Increased renal GRK4 expression in SHRs72;
increased renal GRK activity in
hypertensive subjects16; increased renal
GRK4 expression and normalized by
rosiglitazone (insulin sensitizer) in obese
Zucker rats55; increased renal GRK4




Increases blood pressure (on high salt diet)
and renal AT1R expression
78; increases in





Increase basal D1R phosphorylation and
impairs D1R-mediated cAMP production
16
GRK4 gene depletion Increases sodium excretion, attenuates the
increased blood pressure and renal serine-
phosphorylated D1R in SHRs
72; blunts the
D1R desensitization in human RPTCs
54;
blocks D1R phosphorylation and restores
D1R- mediated cAMP accumulation in





Increases blood pressure23 Increased GRK5 expression in Ang II–
treated VSMCs93; increased GRK5
expression in aortas of Ang II– and
norepinephrine-induced hypertension93;
no significant difference in GRK5
expression in the lymphocytes of
hypertensive and normotensive patients9








Global knockout Causes striatum D2R supersensitivit
110 Decreased renal GRK6 expression in
hypertensive participants and SHRs111;




Prevents intestinal D1R desensitization
107
Ang II indicates angiotensin II; AR, adrenergic receptor; AT1R, angiotensin II type 1 receptor; D1R, dopamine D1 receptor; ETAR, endothelin A receptor; GPCR, G protein–coupled receptor;
GRK, G protein–coupled receptor kinase; PE, phenylephrine; RPTC, renal proximal tubule cell; SHHF, spontaneously hypertensive heart failure; SHR, spontaneously hypertensive rat; shRNA,
small hairpin RNA; VSM, vascular smooth muscle; VSMC, vascular smooth muscle cell.
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responsive to metoprolol if they also had a GRK4L65 variant,
but the additive effect of A142 and L65 variants on blood
pressure was not found in women.115 Another study from the
Pharmacogenomic Evaluation of Antihypertensive Responses
trial involving hypertensive African and Euro-American partic-
ipants found that GRK465L and GRK4142V variant alleles and
increasing copies of the variant GRK465L and GRK4142V
haplotypes are associated with reduced response to b-blocker
monotherapy. Moreover, all 3 GRK4 variants (65L, 142V, and
486V) are associated with increased risk for the primary
outcome (first occurrence of all-cause death, nonfatal
myocardial infarction, or nonfatal stroke) in pooled white
and Hispanic participants.11 European hypertensive patients
who are homozygous for GRK465L and GRK4142V have been
reported to need more antihypertensive treatment, especially
diuretic therapy, to reach the same mean arterial blood
pressure as homozygous carriers of only 1 variant or
heterozygous/wild-type carriers of R65L, A142V, and A486V
alleles.116 These results suggest that the presence or absence
of GRK4 gene variants may be important determinants in
guiding therapeutic antihypertensive strategies.
GRK2 may also influence to response to some antihyper-
tensive medicines. The SNPs in the GRK2 gene are more
common in African-Americans, who have a higher risk for
increased blood pressure.100 Specifically, 2 GRK2 SNPs are
associated with blood pressure response to antihypertensive
medicines. Compared with African-American patients with the
rs4930416 homozygote, those with a heterozygote
(rs4930416, A>C) have similar blood pressure at baseline
but greater blood pressure reduction with hydrochloroth-
iazide. Diastolic blood pressure, but not systolic blood
pressure, response to atenolol also differs by rs4930416
genotype.100 There are also trends toward different diastolic
blood pressure and systolic blood pressure responses with
another GRK2 gene SNP, rs1894111, in Euro-American
patients receiving hydrochlorothiazide; however, this SNP is
neither associated with altered blood pressure response to
atenolol nor response in African American patients.100
Conclusions
Overwhelming data demonstrate that GRKs (GRK2, GRK3,
GRK4, GRK5, GRK6), via different mechanisms, play
important roles in the regulation of blood pressure
(Table).7,8,18,59,71,74,90,113,117 Aberrant GRKs in the cardiovas-
cular system and kidney are involved in the pathogenesis of
hypertension. Modulation of GRK activity has yielded promis-
ing results in the regulation of blood pressure, alleviating
cardiovascular and renal dysfunction in a wide variety of
animal models and cell culture systems. Genetic studies have
found a strong association between GRK gene variants and
hypertension. Identification of GRK variants is important in
choosing antihypertensive medication and represents a valu-
able pharmaceutical target for novel therapeutic approaches in
the treatment of hypertension. Increased understanding of
GRKs in the regulation of blood pressure may give us a novel
concept for the pathogenesis of hypertension and provide new
therapeutic antihypertensive strategies in the future.
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